Immunotherapy has emerged as one of the major options for cancer treatment in the past decade. With the successful application of immune checkpoint inhibitors and the introduction of immune regulatory ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...

MaxCyte, Inc. is rated a "Buy" due to significant upside potential despite recent share price declines. Find out why.

MaxCyte (NASDAQ:MXCT – Free Report) had its price objective cut by Stifel Nicolaus from $11.00 to $9.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on ...

PLYMOUTH MEETING, PA, USA I March 13, 2025 I INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help ...

Investment analysts at William Blair issued their Q1 2026 earnings estimates for MaxCyte in a report released on Wednesday, March 12th. William Blair analyst M. Larew expects that the company will ...

MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery ...

MaxCyte will host a conference call today, March 11, 2025, at 4:30 p.m. Eastern Time. Investors interested in listening to the conference call are required to register online. A live and archived ...

A novel acoustofluidics method enhances intracellular nanoparticle delivery, improving biophysical research and therapeutic ...

A recent study published in Engineering presents an innovative acoustofluidics-based approach for intracellular nanoparticle ...

A new study reveals that ammonia, a toxin accumulating in liver disease patients, directly harms liver cells by damaging mitochondria. This creates a vicious cycle, leading to severe health ...